Skip to main content
CTOS 2025 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Barry Shulkin, MD

section chief, nuclear medicine
Department of Radiology, St. Jude Children’s Research Hospital
Memphis, Tennessee, United States

Barry L. Shulkin MD MBA is section chief of nuclear medicine, Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, Tennessee. Barry is a graduate of the University of Texas Austin, University of Texas Southwestern Medical School, and was an internal medicine resident at the University of Texas Southwestern Affiliated Hospitals (Parkland Memorial Hospital and the Dallas Veterans Administration Hospital). He completed a fellowship in endocrinology at the University of North Carolina and followed by a 2 year residency in nuclear medicine at the University of Michigan. After completion of nuclear medicine, Barry had the opportunity to remain at UM to lead the new nuclear medicine satellite unit at the adjacent Mott Children’s Hospital. An expected one year appointment lasted 18 years where he rose through the academic ranks to Professor of Internal Medicine/Nuclear Medicine, then Professor Radiology. He served as interim chief of nuclear medicine for 1.5 years. Within pediatric nuclear medicine, he developed expertise in imaging and treatment of endocrinologic disorders and tumors. He was one of the first investigators to report the use of FDG for the characterization of tumors in pediatric patients as well as PET tracers – carbon-11 hydroxyephedrine, and carbon-11 epinephrine for pheochromocytoma and neuroblastoma.

Barry L. Shulkin MD MBA is section chief of nuclear medicine, Department of Radiology, St. Jude Children’s Research Hospital, Memphis, Tennessee. In 2004 Barry joined the faculty of St. Jude Children’s Research Hospital to lead an initiative in biomedical imaging using PET tracers. His group has conducted over 450 carbon-11 methionine scans, principally in patients with CNS tumors. He continues to direct investigations using fluorine-18 fluorodopamine in patients with neuroblastoma, and nitrogen-13 ammonia in the evaluation of selected patients with hematologic disorders.

Presentation(s):